EvolusEOLS
EOLS
About: Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Employees: 332
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
1,044% more call options, than puts
Call options by funds: $972K | Put options by funds: $85K
17% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 7 (+1) [Q4]
15% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 48
2.01% more ownership
Funds ownership: 79.99% [Q3] → 82.0% (+2.01%) [Q4]
4% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 25
1% less funds holding
Funds holding: 165 [Q3] → 163 (-2) [Q4]
30% less capital invested
Capital invested by funds: $817M [Q3] → $573M (-$244M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$22
80%
upside
Avg. target
$25
102%
upside
High target
$27
121%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Barclays Balaji Prasad 27% 1-year accuracy 12 / 44 met price target | 105%upside $25 | Overweight Maintained | 5 Mar 2025 |
HC Wainwright & Co. Douglas Tsao 20% 1-year accuracy 35 / 171 met price target | 121%upside $27 | Buy Reiterated | 5 Mar 2025 |
Needham Serge Belanger 41% 1-year accuracy 46 / 113 met price target | 80%upside $22 | Buy Reiterated | 5 Mar 2025 |
Financial journalist opinion
Based on 6 articles about EOLS published over the past 30 days
Neutral
Business Wire
1 week ago
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in a fireside chat and investor meetings at the upcoming Needham Annual Virtual Healthcare Conference. The fireside chat will take place on Tuesday, April 8, 2025, at 12:45 PM ET - Track 1. The fireside chats can be accessed on the Investor Relations page of the Evolus website here.
Neutral
Business Wire
1 week ago
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of 29,763 restricted stock units (RSUs) of the company's common stock to 14 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant and vesting commencement d.
Neutral
Seeking Alpha
4 weeks ago
Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript
Evolus, Inc. (NASDAQ:EOLS ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Nareg Sagherian - VP and Head of Global IR and Corporate Communications David Moatazedi - President and CEO Rui Avelar - Chief Medical Officer and Head of R&D Sandra Beaver - CFO Conference Call Participants Annabel Samimy - Stifel Gangireddy Madhumitha - Stryker Navann Ty - BNP Paribas Doug Tsao - H.C. Wainwright Serge Belanger - Needham & Company Operator Good afternoon, everyone, and thank you for standing by.
Negative
Zacks Investment Research
4 weeks ago
Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates
Evolus, Inc. (EOLS) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.14 per share a year ago.
Positive
Reuters
4 weeks ago
Evolus posts quarterly profit on strong sales of cosmetic injection
Cosmetic drugmaker Evolus reported a fourth-quarter profit versus a year-ago loss on Tuesday, on strong demand for its wrinkle treatment Jeuveau which competes with Botox.
Neutral
Business Wire
4 weeks ago
Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced its financial results for the fourth quarter and full-year ended December 31, 2024. “We reached a significant inflection point in 2024, achieving full-year profitability1 ahead of expectations while delivering our fifth consecutive year of revenue growth exceeding 30%,” said David Moatazedi, President and Chief Executive Officer of Ev.
Neutral
Business Wire
1 month ago
Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in fireside chats and investor meetings at upcoming investor conferences in Miami, FL: The Leerink Partners Global Biopharma Conference, the fireside chat will take place on Tuesday, March 11, 2025, at 9:20 AM ET. The Barclays 27th Annual Global Healthcare Conference, the fireside c.
Neutral
Business Wire
1 month ago
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit in New York City on Thursday, February 27, 2025. As part of the event, David Moatazedi, President and CEO of Evolus, will host a fireside chat on Thursday, February 27, 2025, from 9:30 AM – 10:00 AM ET. A live we.
Neutral
Business Wire
1 month ago
Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and year end 2024 financial results on Tuesday, March 4, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's r.
Positive
Zacks Investment Research
1 month ago
Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last?
Evolus (EOLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Charts implemented using Lightweight Charts™